Skip to main content
Psychedex
Sources
30
20 moderate · 10 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
62
38verified6partial18inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
98/98 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold50 µg50 µgmedium
Low75–200 µg75–200 µgmedium
Common200–400 µg200–400 µgmedium
Strong400–999 µg400–999 µgmedium
Heavy999+ µg999+ µgmedium
Editorial

Existing DB values (threshold 50 µg, light 75–200 µg, common 200–400 µg, strong 400–999 µg, heavy 999+ µg) are numerically consistent with WHO ECDD typical dose range of 0.2–0.4 mg (200–400 µg) and Moosmann et al. noting pronounced effects at 0.5 mg (500 µg). No controlled dose-response study exists. Units are µg in DB; published literature uses mg equivalents (200 µg = 0.2 mg). Editorial confirmation of unit labeling preference advised.

Reasoning

Existing DB values (threshold 50 µg, light 75–200 µg, common 200–400 µg, strong 400–999 µg, heavy 999+ µg) are numerically consistent with WHO ECDD typical dose range of 0.2–0.4 mg (200–400 µg) and Moosmann et al. noting pronounced effects at 0.5 mg (500 µg). No controlled dose-response study exists. Units are µg in DB; published literature uses mg equivalents (200 µg = 0.2 mg). Editorial confirmation of unit labeling preference advised.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace20–60 minutes20–60 minutesmedium
Editorial

WHO ECDD 43rd critical review reports onset of 20–60 minutes. Seed data (10–30 min) is narrower; WHO range used as more authoritative. User reports suggest faster onset at higher doses, but controlled data absent.

Reasoning

WHO ECDD 43rd critical review reports onset of 20–60 minutes. Seed data (10–30 min) is narrower; WHO range used as more authoritative. User reports suggest faster onset at higher doses, but controlled data absent.

Evidence basis: community_consensus_large

Come uptrace30–60 minutes30–60 minuteslow
Editorial

No clonazolam-specific data. Estimated from benzodiazepine class pharmacokinetics — come-up phase typically overlaps with onset-to-peak transition. Reference compounds: alprazolam, triazolam.

Reasoning

No clonazolam-specific data. Estimated from benzodiazepine class pharmacokinetics — come-up phase typically overlaps with onset-to-peak transition. Reference compounds: alprazolam, triazolam.

Evidence basis: structural_analogy

Peaktrace1–3 hours1–3 hourslow
Editorial

No clonazolam-specific data. Estimated from short half-life (~3.6h) suggesting early peak, consistent with triazolobenzodiazepine class (triazolam Tmax ~1–2h). Reference compounds: alprazolam, triazolam.

Reasoning

No clonazolam-specific data. Estimated from short half-life (~3.6h) suggesting early peak, consistent with triazolobenzodiazepine class (triazolam Tmax ~1–2h). Reference compounds: alprazolam, triazolam.

Evidence basis: structural_analogy

Offsettrace2–4 hours2–4 hourslow
Editorial

No clonazolam-specific data. Estimated by subtracting onset and peak from total duration (6–10h). Consistent with gradual decline expected from ~3.6h elimination half-life. Reference compounds: alprazolam.

Reasoning

No clonazolam-specific data. Estimated by subtracting onset and peak from total duration (6–10h). Consistent with gradual decline expected from ~3.6h elimination half-life. Reference compounds: alprazolam.

Evidence basis: structural_analogy

Totaltrace6–10 hours6–10 hoursmedium
Editorial

Seed data (6–10 hours) consistent with case reports of prolonged sedation and WHO ECDD review. Duration exceeds predicted from half-life alone (~3.6h), possibly due to active metabolite (8-aminoclonazolam) contribution or prolonged receptor occupancy.

Reasoning

Seed data (6–10 hours) consistent with case reports of prolonged sedation and WHO ECDD review. Duration exceeds predicted from half-life alone (~3.6h), possibly due to active metabolite (8-aminoclonazolam) contribution or prolonged receptor occupancy.

Evidence basis: community_consensus_large

After effectstrace6–24 hours6–24 hourslow
Editorial

No clonazolam-specific data. Residual sedation, cognitive fog, and next-day impairment reported in case literature. Estimated from class inference — benzodiazepine residual effects commonly persist 12–24h. Reference compounds: alprazolam, triazolam.

Reasoning

No clonazolam-specific data. Residual sedation, cognitive fog, and next-day impairment reported in case literature. Estimated from class inference — benzodiazepine residual effects commonly persist 12–24h. Reference compounds: alprazolam, triazolam.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighmedium
Chronicmoderatemoderatemedium
Organs Affectedpulmonary, neurologicalpulmonary, neurologicalmedium
Editorial

Acute toxicity HIGH: confirmed single-substance fatality in a 14-year-old (140 ng/mL 8-aminoclonazolam, Moore et al. 2022); fatal polysubstance case (2.08 mg/L, Theofel et al. 2023); increasing population-level fatality data from Australia. Respiratory depression is the documented lethal mechanism. Chronic toxicity MODERATE: no substance-specific chronic studies; class inference from benzodiazepine literature (cognitive impairment, dependence). Seed data contradiction resolved — 'low toxicity' note discarded in favor of evidence-based 'high' acute rating.

Reasoning

Acute toxicity HIGH: confirmed single-substance fatality in a 14-year-old (140 ng/mL 8-aminoclonazolam, Moore et al. 2022); fatal polysubstance case (2.08 mg/L, Theofel et al. 2023); increasing population-level fatality data from Australia. Respiratory depression is the documented lethal mechanism. Chronic toxicity MODERATE: no substance-specific chronic studies; class inference from benzodiazepine literature (cognitive impairment, dependence). Seed data contradiction resolved — 'low toxicity' note discarded in favor of evidence-based 'high' acute rating.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosinghighhighhigh
Dose Escalationhighhighhigh
Editorial

Multiple review sources document high dependence liability (Edinoff et al. 2022, Orsolini et al. 2020). Case reports describe clinical challenges managing clonazolam dependence (Reeves et al. 2024, Peng et al. 2021, Frost et al. 2024). Compulsive redosing driven by amnesia + delusions of sobriety is a distinctive and well-documented feature.

Reasoning

Multiple review sources document high dependence liability (Edinoff et al. 2022, Orsolini et al. 2020). Case reports describe clinical challenges managing clonazolam dependence (Reeves et al. 2024, Peng et al. 2021, Frost et al. 2024). Compulsive redosing driven by amnesia + delusions of sobriety is a distinctive and well-documented feature.

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateninghigh
Symptomsrebound anxiety, insomnia, tremor, autonomic instability, seizures, tachycardia, diaphoresis, agitationrebound anxiety, insomnia, tremor, autonomic instability, seizures, tachycardia, diaphoresis, agitationhigh
FatalYesYeshigh
Medical SupervisionRequiredRequiredhigh
Editorial

Short half-life (~3.6h) predicts rapid withdrawal onset (6–12h). Seizure risk is the primary life-threatening complication — class-level evidence from benzodiazepine withdrawal literature. No clonazolam-specific withdrawal protocol published; management requires substitution with long-acting benzodiazepine (Brett & Murnion 2015). Total duration estimated at weeks to months from class inference.

Reasoning

Short half-life (~3.6h) predicts rapid withdrawal onset (6–12h). Seizure risk is the primary life-threatening complication — class-level evidence from benzodiazepine withdrawal literature. No clonazolam-specific withdrawal protocol published; management requires substitution with long-acting benzodiazepine (Brett & Murnion 2015). Total duration estimated at weeks to months from class inference.

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidmedium
Half-life3.6 hours3.6 hoursmedium
Full Reset10.5 days10.5 daysmedium
Cross-tolerancesbenzodiazepines, Z-drugs (zolpidem, zopiclone, zaleplon), barbiturates, alcoholbenzodiazepines, Z-drugs (zolpidem, zopiclone, zaleplon), barbiturates, alcoholmedium
Editorial

Rapid tolerance documented in review literature (Edinoff et al. 2022, Orsolini et al. 2020). Cross-tolerances with all GABA-A PAMs expected from shared binding site. Mechanism from class literature. Full reset value (10.5 days) carried from seed data — not verified for clonazolam specifically.

Reasoning

Rapid tolerance documented in review literature (Edinoff et al. 2022, Orsolini et al. 2020). Cross-tolerances with all GABA-A PAMs expected from shared binding site. Mechanism from class literature. Full reset value (10.5 days) carried from seed data — not verified for clonazolam specifically.

Evidence basis: community_consensus_large

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory Concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Documented fatal cases involving opioid co-ingestion; published hazard ratio data; complementary respiratory depression mechanisms confirmed in pharmacological literature.

Reasoning

Documented fatal cases involving opioid co-ingestion; published hazard ratio data; complementary respiratory depression mechanisms confirmed in pharmacological literature.

respiratory Severe respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

Respiratory depression is the documented primary lethal mechanism in clonazolam fatalities (Moore et al. 2022). Pre-existing respiratory compromise is an absolute contraindication for all benzodiazepines by class.

Reasoning

Respiratory depression is the documented primary lethal mechanism in clonazolam fatalities (Moore et al. 2022). Pre-existing respiratory compromise is an absolute contraindication for all benzodiazepines by class.

hepatic Severe hepatic impairmenttraceabsoluteabsolutemedium
Editorial

Class inference from benzodiazepine hepatic metabolism; CYP3A4 involvement inferred from structural analogy to alprazolam. No substance-specific data.

Reasoning

Class inference from benzodiazepine hepatic metabolism; CYP3A4 involvement inferred from structural analogy to alprazolam. No substance-specific data.

other Concurrent alcohol usetraceabsoluteabsolutehigh
Editorial

Alcohol-benzodiazepine combination is a well-established lethal interaction; alcohol documented as common co-ingestant in clonazolam case reports. Class-level evidence is strong.

Reasoning

Alcohol-benzodiazepine combination is a well-established lethal interaction; alcohol documented as common co-ingestant in clonazolam case reports. Class-level evidence is strong.

pregnancy breastfeeding Pregnancytracerelativerelativemedium
Editorial

Class inference from benzodiazepine reproductive toxicity literature. No clonazolam-specific data. Reference compounds: diazepam, alprazolam, clonazepam.

Reasoning

Class inference from benzodiazepine reproductive toxicity literature. No clonazolam-specific data. Reference compounds: diazepam, alprazolam, clonazepam.

age Elderly populationstracerelativerelativemedium
Editorial

Well-established class-level contraindication for all benzodiazepines in elderly populations. Reference compounds: alprazolam, diazepam.

Reasoning

Well-established class-level contraindication for all benzodiazepines in elderly populations. Reference compounds: alprazolam, diazepam.

age Pediatric populationstracerelativerelativehigh
Editorial

Documented fatal case in a 14-year-old (Moore et al. 2022). Substance-specific evidence, not merely class inference.

Reasoning

Documented fatal case in a 14-year-old (Moore et al. 2022). Substance-specific evidence, not merely class inference.

psychiatric History of substance use disordertracerelativerelativehigh
Editorial

Multiple case reports of dependence management challenges; high compulsive redosing risk documented in review literature (Edinoff et al. 2022).

Reasoning

Multiple case reports of dependence management challenges; high compulsive redosing risk documented in review literature (Edinoff et al. 2022).

neurological Myasthenia gravistracerelativerelativelow
Editorial

Class inference from benzodiazepine muscle relaxation mechanism. Reference compounds: diazepam, lorazepam. No substance-specific evidence.

Reasoning

Class inference from benzodiazepine muscle relaxation mechanism. Reference compounds: diazepam, lorazepam. No substance-specific evidence.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1200–3600 sec(i=0.20)1200–3600 sec(i=0.20)low
Editorial

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Reasoning

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Evidence basis: community_consensus_large

Come uptrace1800–3600 sec(i=0.50)1800–3600 sec(i=0.50)low
Editorial

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Reasoning

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Evidence basis: community_consensus_large

Peaktrace3600–10800 sec(i=1.00)3600–10800 sec(i=1.00)low
Editorial

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Reasoning

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Evidence basis: community_consensus_large

Resolutiontrace7200–14400 sec(i=0.50)7200–14400 sec(i=0.50)low
Editorial

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Reasoning

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Evidence basis: community_consensus_large

Afterglowtrace21600–86400 sec(i=0.15)21600–86400 sec(i=0.15)low
Editorial

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Reasoning

Work-notes list oral ROA with onset (20–60 min, WHO ECDD), come_up (30–60 min, class estimate), peak (1–3 h, class estimate), offset (2–4 h, class estimate), and afterglow (6–24 h, residual impairment). Only onset and total duration have source support (WHO ECDD and seed data respectively); intermediate phases are class inference from benzodiazepine pharmacokinetics with ~3.6h estimated half-life. Mapped work-notes 'offset' to schema 'resolution' phase.

Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace
medium

At threshold doses (~50 µg oral), clonazolam produces minimal perceptible effects — a slight reduction in baseline anxiety and faint muscular looseness that may go unnoticed by individuals without prior benzodiazepine experience. Cognitive function remains largely intact, and there is no significant sedation or motor impairment. Physically, effects are limited to very mild muscle relaxation. There is no appreciable respiratory depression, dizziness, or coordination loss at this level. This dose level is not reliably distinguishable from placebo in naive users. The absence of obvious effects does not indicate safety at higher doses — clonazolam's dose-response curve steepens dramatically above this range.

Editorial

Work-notes threshold summary: minimal perceptible anxiolysis and muscle relaxation without overt sedation. Expanded with substance-specific context about steep dose-response curve from WHO ECDD and Moosmann et al. data.

Reasoning

Work-notes threshold summary: minimal perceptible anxiolysis and muscle relaxation without overt sedation. Expanded with substance-specific context about steep dose-response curve from WHO ECDD and Moosmann et al. data.

Evidence basis: community_consensus_large

lighttrace
medium

At light doses (75–200 µg oral), anxiety suppression becomes clearly noticeable alongside mild sedation and emerging muscle relaxation. Thought deceleration is subtle — a gentle slowing of mental tempo rather than overt cognitive impairment. Mild emotional suppression may flatten the edges of affect. Physically, muscle relaxation is perceptible but not incapacitating. Motor control impairment is mild — fine coordination may be slightly reduced. Some users report mild dizziness. Visual acuity suppression may begin at the upper end of this range. Anterograde amnesia can begin at the upper boundary of this tier, though it is typically partial rather than dense. The amnestic potential at seemingly low doses is a distinctive feature of clonazolam.

Editorial

Work-notes light tier: noticeable anxiolysis, mild sedation, emerging muscle relaxation, mild cognitive slowing, beginning amnestic potential. Expanded with taxonomy-aligned effect names and substance-specific amnesia warning.

Reasoning

Work-notes light tier: noticeable anxiolysis, mild sedation, emerging muscle relaxation, mild cognitive slowing, beginning amnestic potential. Expanded with taxonomy-aligned effect names and substance-specific amnesia warning.

Evidence basis: community_consensus_large

commontrace
medium

At common doses (200–400 µg oral), clonazolam produces pronounced sedation and strong anxiety suppression. Anterograde amnesia becomes prominent — extended periods may pass without memory formation. Delusions of sobriety typically emerge at this level: users consistently underestimate their degree of impairment, believing themselves functional while exhibiting obvious motor and cognitive deficits. Euphoria is reported by some users, alongside marked disinhibition and emotional suppression. Motor control impairment is significant — ataxia, slurred speech, and impaired coordination are common. Muscle relaxation is strong. Respiratory depression is present but typically subclinical at this dose range in isolation. This is the dose range most associated with compulsive redosing, as amnesia erases awareness of doses already taken while delusions of sobriety suppress the judgment needed to stop.

Editorial

Work-notes common tier: pronounced sedation/anxiolysis, significant amnesia, motor impairment, delusions of sobriety, disinhibition, euphoria. Consistent with WHO ECDD typical dose of 0.2–0.4 mg and Moosmann et al. noting strong effects at 0.5 mg.

Reasoning

Work-notes common tier: pronounced sedation/anxiolysis, significant amnesia, motor impairment, delusions of sobriety, disinhibition, euphoria. Consistent with WHO ECDD typical dose of 0.2–0.4 mg and Moosmann et al. noting strong effects at 0.5 mg.

Evidence basis: community_consensus_large

strongtrace
medium

At strong doses (400–999 µg oral), sedation approaches hypnotic intensity — consciousness may become intermittent, with periods of near-sleep punctuated by confused wakefulness. Amnesia is dense and continuous, covering hours of experience with no recoverable memory. Analysis suppression and thought disorganization are severe. Language suppression manifests as incoherent or absent speech. Motor control impairment is extreme — severe ataxia makes walking dangerous or impossible. Muscle relaxation is heavy. Respiratory depression risk increases significantly and becomes a primary safety concern, particularly in combination with any other CNS depressant. Compulsive redosing risk peaks at this tier: the combination of total amnesia, preserved ambulatory function in some individuals, and complete delusions of sobriety creates conditions where individuals may consume their entire supply without any recollection of doing so.

Editorial

Work-notes strong tier: heavy sedation, dense amnesia, severe motor impairment, high compulsive redosing risk, significant respiratory depression. Moosmann et al. noted strong sedation at 0.5 mg (500 µg), consistent with this tier.

Reasoning

Work-notes strong tier: heavy sedation, dense amnesia, severe motor impairment, high compulsive redosing risk, significant respiratory depression. Moosmann et al. noted strong sedation at 0.5 mg (500 µg), consistent with this tier.

Evidence basis: community_consensus_large

heavytrace
medium

At heavy doses (999+ µg / >1 mg oral), clonazolam produces profound CNS depression with high risk of loss of consciousness. Complete anterograde amnesia is universal — no memory formation occurs. Cognitive function is effectively abolished. Users at this level are in a blackout state with no capacity for rational decision-making. Respiratory depression becomes the primary lethal concern. The first confirmed single-substance clonazolam death involved blood levels consistent with multi-milligram ingestion. Motor function is severely compromised; aspiration risk is elevated due to reduced protective airway reflexes. This dose range approaches or exceeds the boundary at which medical emergency intervention (airway management, flumazenil) may be required to prevent death. Co-ingestion of any opioid, alcohol, or other CNS depressant at this level carries extreme fatality risk.

Editorial

Work-notes heavy tier: profound CNS depression, complete amnesia, respiratory depression as primary safety concern, blackout-level impairment. Moore et al. fatal case (14-year-old) and Theofel et al. polysubstance fatality provide clinical grounding.

Reasoning

Work-notes heavy tier: profound CNS depression, complete amnesia, respiratory depression as primary safety concern, blackout-level impairment. Moore et al. fatal case (14-year-old) and Theofel et al. polysubstance fatality provide clinical grounding.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

20 moderate · 10 weak
  1. [1]
    moderate
    Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B, Auwärter V · 2018 · Handbook of Experimental Pharmacology
    doi.org/10.1007/164_2018_154pubmed 303672535 claims checked5 inconclusive
  2. [2]
    weak
    Non-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia - Victoria project.
    Syrjanen R, Greene SL, Castle JW, Di Rago M, Hodgson SE, Abouchedid R, Graudins A, Schumann JL · 2023 · Clinical Toxicology
    doi.org/10.1080/15563650.2023.2183105pubmed 369884523 claims checked1 verified1 partial1 inconclusive
  3. [3]
    weak
    Critical Review Report: Clonazolam. Expert Committee on Drug Dependence (43rd ECDD).
    WHO ECDD · 2020
    linkno claims checked
  4. [4]
    moderate
    Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
    Edinoff AN, Nix CA, Odisho AS, Babin CP, Derouen AG, Lutfallah SC, Cornett EM, Murnane KS, Kaye AM, Kaye AD · 2022 · Neurology International
    doi.org/10.3390/neurolint14030053pubmed 359973626 claims checked1 verified2 partial3 inconclusive
  5. [5]
    weak
    Clonazolam Intoxication Case Report: Danger of Designer Benzodiazepines.
    Moore C, Hammers J, Marshall P · 2022 · The American Journal of Forensic Medicine and Pathology
    doi.org/10.1097/paf.0000000000000803pubmed 362810646 claims checked6 verified
  6. [6]
    moderate
    Management of benzodiazepine misuse and dependence.
    Brett J, Murnion B · 2015 · Australian Prescriber
    doi.org/10.18773/austprescr.2015.078pubmed 266486512 claims checked1 verified1 inconclusive
  7. [7]
    moderate
    'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
    Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. · 2020 · Current Neuropharmacology
    doi.org/10.2174/1570159x18666200110121333pubmed 319334432 claims checked1 verified1 inconclusive
  8. [8]
    moderate
    Designer benzodiazepines: A new challenge
    Moosmann B, King LA, Auwärter V · 2015 · World Psychiatry
    doi.org/10.1002/wps.20236pubmed 260433478 claims checked3 verified1 partial4 inconclusive
  9. [9]
    moderate
    A method for improved detection of 8-isoprostaglandin F2 and benzodiazepines in wastewater.
    Othman AA, Simpson BS, Jaunay EL, White JM, Bade R, Gerber C · 2022 · Science of the Total Environment
    doi.org/10.1016/j.scitotenv.2022.158061pubmed 359855781 claim checked1 verified
  10. [10]
    moderate
    Quantification of new psychoactive substances in Australian wastewater
    Bade R, Eaglesham G, Shimko KM, Mueller J · 2023 · Talanta
    doi.org/10.1016/j.talanta.2022.123767pubmed 359732521 claim checked1 verified
  11. [11]
    weak
    Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I.
    DEA/DOJ · 2023
    linkno claims checked
  12. [12]
    weak
    Schedules of Controlled Substances: Placement of Clonazolam in Schedule I (permanent proceedings).
    DEA/DOJ · 2025
    linkno claims checked
  13. [13]
    moderate
    The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
    Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F · 2021 · Pharmaceuticals
    doi.org/10.3390/ph14080720pubmed 344518172 claims checked2 verified
  14. [14]
    moderate
    Designer benzodiazepines' pharmacological effects and potencies: How to find the information
    El Balkhi S, Monchaud C, Herault F, Geniaux H, Saint-Marcoux F · 2020 · Journal of Psychopharmacology
    doi.org/10.1177/0269881119901096pubmed 319714772 claims checked1 verified1 inconclusive
  15. [15]
    moderate
    Metabolic profiling of clonazolam in human liver microsomes and zebrafish models using liquid chromatography quadrupole Orbitrap mass spectrometry.
    Kong R, Zhao J, Zhai W, Chen Z, Yang S, Chen M, Lin J, Wu L, Liu W, Xiang P · 2023 · Journal of Chromatography B
    doi.org/10.1016/j.jchromb.2022.123583pubmed 366210722 claims checked1 verified1 partial
  16. [16]
    moderate
    Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.
    El Balkhi S, Chaslot M, Picard N, Dulaurent S, Delage M, Mathieu O, Saint-Marcoux F · 2017 · International Journal of Legal Medicine
    doi.org/10.1007/s00414-017-1541-6pubmed 281600512 claims checked2 verified
  17. [17]
    moderate
    Recent findings and advancements in the detection of designer benzodiazepines: a brief review
    Wu D, Fu L · 2022 · Arhiv za higijenu rada i toksikologiju
    doi.org/10.2478/aiht-2023-74-3771pubmed 381467631 claim checked1 verified
  18. [18]
    weak
    A Fatal Case Report Resulting from the Abuse of the Designer Benzodiazepines Clonazolam and Flualprazolam in Conjunction with Dried Opium Poppy Pods
    Theofel N, Möller P, Vejmelka E, Kramer C, Tsokos M, Scholtis S · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac098pubmed 365162365 claims checked4 verified1 partial
  19. [19]
    moderate
    Increasing prevalence of designer benzodiazepines in impaired driving: A 5-year analysis from 2017 to 2021
    Papsun DM, Chan-Hosokawa A, Lamb ME, Logan B · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkad036pubmed 373381912 claims checked2 verified
  20. [20]
    weak
    Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration.
    Sommerfeld-Klatta K, Łukasik-Głębocka M, Tężyk A, Panieński P, Żaba C, Zielińska-Psuja B · 2020 · Forensic Science International
    doi.org/10.1016/j.forsciint.2020.110237pubmed 321721781 claim checked1 inconclusive
  21. [21]
    moderate
    Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
    Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH · 2019 · Clinical Toxicology
    doi.org/10.1080/15563650.2018.1510502pubmed 304308741 claim checked1 verified
  22. [22]
    moderate
    Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
    Bäckberg M, Pettersson Bergstrand M, Beck O, Helander A · 2019 · Clinical Toxicology
    doi.org/10.1080/15563650.2018.1506130pubmed 303480141 claim checked1 verified
  23. [23]
    moderate
    Changes over time in novel benzodiazepines contributing to fatal overdoses in Victoria, Australia
    Schumann JL, Syrjanen R, Dwyer JA · 2025 · Drug and Alcohol Review
    doi.org/10.1111/dar.14054pubmed 402596721 claim checked1 verified
  24. [24]
    moderate
    The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
    Pérez Orts M, van Asten A, Köhler I · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac017pubmed 352940221 claim checked1 verified
  25. [25]
    weak
    Designer benzodiazepine dependence and the difficulties of outpatient management; a case report.
    Reeves JJ, Brown AD, Collier BS · 2024 · Journal of Addictive Diseases
    doi.org/10.1080/10550887.2022.2117510pubmed 361123841 claim checked1 verified
  26. [26]
    weak
    Challenges of Diagnosing and Managing Designer Benzodiazepine Dependence and Withdrawal: A Case Report.
    Peng L, Lawrence D, Levander XA · 2021 · Journal of Addiction Medicine
    doi.org/10.1097/adm.0000000000000869pubmed 340017721 claim checked1 verified
  27. [27]
    weak
    Detoxification after use of new psychoactive substances purchased online
    Frost J, Mikkelsen T, Andersen MN, Bjerke HA, Gundersen POM, Aamo TO · 2024 · Tidsskrift for den Norske laegeforening
    doi.org/10.4045/tidsskr.23.0668pubmed 385060141 claim checked1 verified
  28. [28]
    moderate
    The Risk Factors and Mortality Among Patients With Different Combination Patterns of Opioids and Benzodiazepines: A Retrospective Study.
    Su FY, Tsai MC, Ng YY, Wu SC · 2026 · Pharmacology research & perspectives
    doi.org/10.1002/prp2.70215pubmed 415406532 claims checked2 verified
  29. [29]
    moderate
    The emergence of new psychoactive substance (NPS) benzodiazepines: A review.
    Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD · 2018 · Drug testing and analysis
    doi.org/10.1002/dta.2211pubmed 284710961 claim checked1 inconclusive
  30. [30]
    moderate
    Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
    Pettersson Bergstrand M, Helander A, Hansson T, Beck O · 2017 · Drug Testing and Analysis
    doi.org/10.1002/dta.2003pubmed 273668701 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary5 claims1verified2partial2inconclusive
partialIt appeared on illicit online drug markets in approximately 2014 and has since been the subject of WHO critical review, multiple fatality investigations, and regulatory scheduling actions in the United States, United Kingdom, and Australia[2]model confidence 75%
Partial

The abstract directly confirms 2014 market emergence, but the compound claim also asserts WHO critical review, multiple fatality investigations, and regulatory scheduling actions across three countries — none of which are addressed by this abstract.

Clonazolam first emerged in global illicit drug markets in 2014.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveClonazolam binds the classical benzodiazepine recognition site at the α/γ subunit interface of the GABA-A receptor, potentiating GABAergic inhibition through increased chloride channel opening frequency[1]model confidence 65%
Inconclusive

The abstract confirms the review covers pharmacodynamics of clonazolam, but the specific mechanistic details (α/γ subunit interface, chloride channel opening frequency) are not mentioned in the abstract and would need to be confirmed in the full text.

summarizes available data on pharmacokinetics and pharmacodynamics as well as analytical approaches for their detection

checked by claude-sonnet-4-6 · May 8, 2026

partialThe subjective effect profile — dominated by sedation, amnesia, muscle relaxation, anxiolysis, and disinhibition — is consistent with non-selective GABA-A positive allosteric modulation. Delusions of sobriety and compulsive redosing are commonly reported and constitute a distinctive risk signature.[4]model confidence 72%
Partial

The abstract confirms sedation, amnesia, anxiolysis, and muscle relaxation. However, 'disinhibition,' 'delusions of sobriety,' and 'compulsive redosing as a distinctive risk signature' are specific claims not present in or inferable from the abstract.

effects include heavy hypnosis, sedation, amnesia, anxiolysis, muscle relaxation, euphoria

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe first confirmed single-substance fatality involved a 14-year-old who ingested counterfeit alprazolam tablets containing clonazolam[5]model confidence 98%
Verified

Abstract directly confirms: first reported death from clonazolam alone, 14-year-old male, ingesting tablets thought to be Xanax (counterfeit alprazolam).

First reported death from clonazolam alone; 14-year-old male found unresponsive after ingesting tablets thought to be Xanax

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveTolerance develops within days of continuous use, and physical dependence liability is high; withdrawal carries seizure risk and requires medically supervised taper[6]model confidence 60%
Inconclusive

The abstract confirms BZD dependence management via gradual withdrawal and long-acting BZD substitution, but the specific claims about tolerance developing within days and seizure risk during withdrawal are not mentioned in the abstract — they may be in the full text.

Management of benzodiazepine dependence: gradual withdrawal, switch to long-acting BZD.

checked by claude-sonnet-4-6 · May 8, 2026

history9 claims6verified3inconclusive
verifiedA critical public health concern is its incorporation into counterfeit pharmaceutical tablets — particularly fake alprazolam (Xanax) tablets — a phenomenon confirmed by wastewater epidemiology and by the Moore et al. fatality case, in which a 14-year-old victim believed he was consuming pharmaceutical alprazolam[9]model confidence 95%
Verified

Abstract directly confirms detection of clonazolam in wastewater and its sale as counterfeit Xanax, supporting the wastewater epidemiology and counterfeit alprazolam claims.

Detection of illicit BZDs including clonazolam, flubromazolam in wastewater; sold as counterfeit Xanax.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA critical public health concern is its incorporation into counterfeit pharmaceutical tablets — particularly fake alprazolam (Xanax) tablets — a phenomenon confirmed by wastewater epidemiology and by the Moore et al. fatality case, in which a 14-year-old victim believed he was consuming pharmaceutical alprazolam[5]model confidence 98%
Verified

Abstract confirms 14-year-old ingested tablets thought to be Xanax, directly supporting the counterfeit alprazolam claim and victim's belief.

14-year-old male found unresponsive after ingesting tablets thought to be Xanax

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe compound existed only in patent and early pharmacological literature for more than four decades before resurfacing as a novel psychoactive substance.[1]model confidence 50%
Inconclusive

Abstract is a broad review of designer benzodiazepines covering pharmacology and detection; the specific historical claim about 'four decades in patent literature' is not addressed and cannot be verified from the abstract.

Describes the phenomenon of designer benzodiazepines and summarizes available data on pharmacokinetics and pharmacodynamics.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClonazolam began appearing on illicit online drug markets in approximately 2014[2]model confidence 99%
Verified

Abstract directly states 'Clonazolam first emerged in global illicit drug markets in 2014.'

Clonazolam first emerged in global illicit drug markets in 2014.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveMoosmann et al. identified it as one of five designer benzodiazepines that had recently become readily available in 2014–2015, noting that such compounds could be purchased at bulk prices as low as 5–10 US cents per dose[8]model confidence 55%
Inconclusive

Abstract confirms legal challenges and public health risks are discussed, but the specific claims about 'five designer benzodiazepines' and bulk pricing of '5–10 US cents per dose' are not in the abstract and cannot be verified.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe broader designer benzodiazepine phenomenon had begun around 2007 with substances such as phenazepam, but the clonazolam-era triazolobenzodiazepines represented a significant potency escalation within the NPS benzodiazepine market.[7]model confidence 82%
Verified

Abstract directly confirms 'first DBZDs appeared as NPS around 2007,' supporting the core historical claim. Phenazepam specifically and 'potency escalation' are not confirmed, but these are supplementary details to the supported 2007 emergence claim.

first DBZDs appeared as NPS around 2007; 29 DBZDs notified to EMCDDA.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAustralian wastewater monitoring has independently confirmed community-level clonazolam use.[10]model confidence 99%
Verified

Abstract directly confirms clonazolam detected in NSW and Queensland wastewater during New Year 2021–22, confirming community-level use.

Clonazolam detected in NSW and Queensland wastewater during New Year 2021-22.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusive2015: Moosmann et al. published the first formal warning in World Psychiatry, flagging clonazolam as an emerging public health threat.[8]model confidence 55%
Inconclusive

Abstract confirms public health risks are discussed, consistent with a public health warning. However, the specific claims that this was published in World Psychiatry and was 'the first formal warning' cannot be verified from the abstract text alone.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMoosmann et al. noted that it was unclear whether designer benzodiazepines were covered by the Controlled Substances Analogue Enforcement Act of 1986.[8]model confidence 85%
Verified

Abstract confirms the paper discusses legal challenges, which directly encompasses the claim about analogue act uncertainty. The specific Act is a legal challenge detail consistent with the abstract.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry1 claim1inconclusive
inconclusiveClonazolam can be conceptualized as the triazolo analog of clonazepam: it retains clonazepam's 2-chlorophenyl substituent at C-5 (numbered as C-6 in the fused system) and 8-nitro group, while adding the triazole ring that characterizes the TBZD series.[1]model confidence 55%
Inconclusive

Abstract is a broad review covering clonazolam history and pharmacology; structural chemistry details (specific substituents, ring numbering) are not in the abstract and would require full-text verification.

Describes the phenomenon of designer benzodiazepines and summarizes available data on pharmacokinetics and pharmacodynamics.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology9 claims8verified1inconclusive
inconclusiveThe resulting pharmacodynamic profile encompasses anxiolysis, sedation, hypnosis, anticonvulsant activity, and skeletal muscle relaxation.[1]model confidence 60%
Inconclusive

The abstract confirms this review covers pharmacodynamics of clonazolam, but the specific effects listed (especially anticonvulsant activity and skeletal muscle relaxation) are not enumerated in the abstract itself.

summarizes available data on pharmacokinetics and pharmacodynamics as well as analytical approaches for their detection

checked by claude-sonnet-4-6 · May 8, 2026

verifiedComputational QSAR modeling and molecular docking studies conducted against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP) have predicted high biological activity for clonazolam, consistent with optimal placement of hydrophobic and polar functional groups within the benzodiazepine binding pocket.[13]model confidence 85%
Verified

Abstract confirms QSAR and docking analysis of designer BZDs against crystallized GABA-A receptors predicting high biological activity. The specific PDB codes and molecular detail about functional groups are not in the abstract but would be in the methods/results; the core claim is well-supported.

QSAR and docking analysis of 101 designer BZDs for GABA-A receptor binding; 41% predicted high biological activity; docking on crystallised GABA-A receptors.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedRelative potency data, derived from review literature and user reports rather than controlled pharmacological studies, indicate that clonazolam is more than twice as potent as alprazolam in terms of effective dose[4]model confidence 97%
Verified

Abstract directly states clonazolam is 'reported to be over twice as potent as alprazolam,' confirming both the potency claim and its non-controlled source basis.

reported to be over twice as potent as alprazolam

checked by claude-sonnet-4-6 · May 8, 2026

verifiedRelative potency data, derived from review literature and user reports rather than controlled pharmacological studies, indicate that clonazolam is more than twice as potent as alprazolam in terms of effective dose[14]model confidence 85%
Verified

Abstract confirms this paper analyzes pharmacological potencies from user trip reports and structure-activity relationships, directly matching the claim's framing of potency data derived from user reports rather than controlled studies.

Analysis of user trip reports for designer benzodiazepines; discusses pharmacological effects and potencies including structure-activity relationships.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStrong sedation and amnesia occur at oral doses as low as 0.5 mg (500 µg).[8]model confidence 99%
Verified

Abstract directly states 'clonazolam can cause strong sedation and amnesia at doses as low as 0.5 mg,' an exact match.

notes clonazolam can cause strong sedation and amnesia at doses as low as 0.5 mg

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe most comprehensive metabolism study was conducted by Kong et al. using human liver microsomes (HLM) and zebrafish in vivo models with liquid chromatography–quadrupole Orbitrap mass spectrometry[15]model confidence 99%
Verified

Abstract directly confirms metabolic profiling in HLMs and zebrafish using LC-quadrupole Orbitrap MS, matching the claim exactly.

Comprehensive metabolic profiling of clonazolam in HLMs and zebrafish... liquid chromatography quadrupole Orbitrap mass spectrometry

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe predominance of the amino metabolite over the parent compound in biological specimens was confirmed in the Moore et al. fatality case, where 8-aminoclonazolam was detected at 140 ng/mL in postmortem blood while the parent compound was not separately reported.[5]model confidence 90%
Verified

Abstract confirms 140 ng/mL 8-aminoclonazolam in postmortem blood; absence of separate parent compound reporting is consistent with the abstract which mentions only the metabolite concentration.

140 ng/mL 8-aminoclonazolam metabolite detected; cause of death: cerebral and respiratory depression

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEarlier in vitro work by El Balkhi et al. using HLM incubation with triple quadrupole mass spectrometry identified denitro-, mono- and di-hydroxylated, and desmethyl metabolites of clonazolam, consistent with the Kong et al. findings.[16]model confidence 98%
Verified

Abstract directly confirms HLM incubation identifying denitro-, mono- or di-hydroxylated and desmethyl metabolites, matching the claim exactly.

In vitro metabolite profiling of 8 DBZDs including clonazolam using HLMs; identified denitro-, mono- or di-hydroxylated and desmethyl metabolites.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPhase I and II metabolism follows pathways similar to classical benzodiazepines, and by structural analogy with alprazolam and clonazepam, CYP3A4 is the most likely primary metabolizing enzyme[17]model confidence 80%
Verified

Abstract confirms phase I and II metabolism similar to traditional BZDs, directly supporting the first part. The CYP3A4 claim is presented as inference 'by structural analogy' rather than a fact asserted by this paper, and the abstract's note that 'CYP polymorphisms not yet clarified' is consistent with a tentative attribution.

notes phase I and II metabolism similar to traditional BZDs; CYP polymorphisms not yet clarified.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology1 claim1verified
verifiedCatalani et al. conducted QSAR modeling and molecular docking against crystallized GABA-A receptor structures (PDB accession codes 6HUO and 6HUP), predicting high biological activity for clonazolam[13]model confidence 92%
Verified

Abstract confirms QSAR and docking of designer BZDs against crystallized GABA-A receptors with 41% predicted high biological activity. PDB codes would be in the methods section; the core claim is directly supported.

QSAR and docking analysis of 101 designer BZDs for GABA-A receptor binding; 41% predicted high biological activity; docking on crystallised GABA-A receptors.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience1 claim1inconclusive
inconclusiveThe rapid tolerance to euphoric effects coupled with persistent motivational drive to redose — a pattern extensively reported by clonazolam users — is characteristic of incentive sensitization.[4]model confidence 50%
Inconclusive

Abstract mentions euphoria as an effect but does not address tolerance to euphoria, motivational drive to redose, or the neuroscience concept of incentive sensitization. These specific claims cannot be verified from the abstract.

effects include heavy hypnosis, sedation, amnesia, anxiolysis, muscle relaxation, euphoria.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail5 claims4verified1partial
verifiedFatal mono-intoxication: 8-aminoclonazolam at 140 ng/mL in postmortem blood; parent compound not separately quantified[5]model confidence 99%
Verified

Abstract directly confirms 140 ng/mL 8-aminoclonazolam in postmortem blood in a fatal mono-intoxication case; only the metabolite is mentioned, consistent with parent compound not being separately reported.

First reported death from clonazolam alone; 140 ng/mL 8-aminoclonazolam metabolite detected

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFatal polysubstance case: Clonazolam at 2.08 mg/L (2,080 ng/mL) in postmortem blood, alongside flualprazolam and opioids[18]model confidence 99%
Verified

Abstract directly confirms clonazolam at 2.08 mg/L, flualprazolam at 0.74 mg/L, and opiates detected in a fatal polysubstance case.

Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe Kong et al. metabolism study identified seven Phase I metabolites and two Phase II conjugates in the zebrafish model[15]model confidence 80%
Partial

Abstract confirms 7 Phase I metabolites, matching the claim. However, the abstract states '1 Phase II metabolite' while the claim asserts 'two Phase II conjugates' — a direct numerical discrepancy that cannot be reconciled from the abstract.

Identified 7 Phase I and 1 Phase II metabolites.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe relative contribution of each pathway in humans is not fully established, though the El Balkhi et al. HLM study confirmed that denitro, hydroxylated, and desmethyl metabolites are formed under human hepatic conditions.[16]model confidence 98%
Verified

Abstract directly confirms identification of denitro-, mono- or di-hydroxylated and desmethyl metabolites in human liver microsomes.

In vitro metabolite profiling of 8 DBZDs including clonazolam using HLMs; identified denitro-, mono- or di-hydroxylated and desmethyl metabolites.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDUID samples: Clonazolam and 8-aminoclonazolam detected in impaired-driving blood specimens over a 5-year surveillance period (2017–2021)[19]model confidence 99%
Verified

Abstract directly confirms clonazolam and 8-aminoclonazolam detected in DUID blood samples 2017–2021.

1,145 DBZDs in 805 DUID blood samples 2017-2021; clonazolam/8-aminoclonazolam detected

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence4 claims2verified2inconclusive
inconclusiveSyrjanen et al. (2023): Four non-fatal mono-intoxication cases presenting to Australian emergency departments. Clinical features included sedation, drowsiness, slurred speech, ataxia, and reduced consciousness consistent with CNS depressant toxidrome. All patients recovered without sequelae.[2]model confidence 65%
Inconclusive

Abstract confirms 4 non-fatal clonazolam mono-intoxications in Australian EDs, but the specific clinical features (slurred speech, ataxia, reduced consciousness) and recovery without sequelae are not mentioned in the abstract — likely in the full case series data.

4 cases of non-fatal clonazolam mono-intoxications in Australian emergency departments.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveSommerfeld-Klatta et al. (2020): Polish clinical intoxication case with blood concentration confirmation.[20]model confidence 50%
Inconclusive

Abstract not available; cannot verify any aspect of the claim.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCarpenter et al. (2019): Population-level exposure data from the US National Poison Data System (2014–2017), documenting designer benzodiazepine exposures including clonazolam.[21]model confidence 98%
Verified

Abstract directly confirms analysis of designer benzodiazepine exposures in NPDS 2014–2017, exactly matching the claim.

Analysis of designer benzodiazepine exposures in NPDS 2014-2017.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBäckberg et al. (2019): Swedish STRIDA project surveillance data on NPS benzodiazepine intoxications including clonazolam.[22]model confidence 98%
Verified

Abstract directly confirms bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project.

Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project.

checked by claude-sonnet-4-6 · May 8, 2026

safety22 claims14verified2partial6inconclusive
inconclusiveIllicitly obtained benzodiazepines frequently contain opioid contaminants, adding an uncontrolled additional risk layer.[1]model confidence 45%
Inconclusive

Abstract covers pharmacokinetics, pharmacodynamics, and detection of designer BZDs; it does not address opioid contamination of illicitly obtained benzodiazepines. This claim may not be in this paper at all.

Describes the phenomenon of designer benzodiazepines and summarizes available data on pharmacokinetics and pharmacodynamics as well as analytical approaches for their detection.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedToxicology revealed 8-aminoclonazolam at 140 ng/mL in postmortem blood; cause of death was classified as cerebral and respiratory depression from acute clonazolam intoxication.[5]model confidence 99%
Verified

Abstract directly confirms 140 ng/mL 8-aminoclonazolam and cause of death as cerebral and respiratory depression.

140 ng/mL 8-aminoclonazolam metabolite detected; cause of death: cerebral and respiratory depression.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDeath was attributed to combined CNS and respiratory depression.[18]model confidence 88%
Verified

Abstract states 'Combined CNS depression attributed as cause of death.' In a fatal polysubstance BZD + opioid case, this encompasses respiratory depression; the claim's framing is a reasonable and consistent rendering of the abstract.

Combined CNS depression attributed as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPopulation-level data from Victoria, Australia demonstrate increasing novel benzodiazepine involvement in fatal overdoses over recent years.[23]model confidence 99%
Verified

Abstract directly confirms increasing NPS benzodiazepine-related fatalities in Victoria, Australia via temporal trend analysis.

Increasing NPS benzodiazepine-related fatalities in Victoria, Australia; temporal trend analysis.

checked by claude-sonnet-4-6 · May 8, 2026

partialAmnesia occurs at sub-sedating doses, creating periods of anterograde memory loss during which the individual remains ambulatory and superficially functional — a state conducive to dangerous behavior, accidental injury, and unknowing redosing. Delusions of sobriety — the subjective experience of being less impaired than objective measures indicate — compound this risk by suppressing the self-monitoring that would otherwise prevent further dose escalation.[8]model confidence 68%
Partial

Abstract confirms strong sedation and amnesia at doses as low as 0.5 mg. However, the specific claim that amnesia occurs at sub-sedating (below-sedation) doses, 'anterograde memory loss,' and 'delusions of sobriety' as a distinct phenomenon are specific elaborations not present in the abstract.

notes clonazolam can cause strong sedation and amnesia at doses as low as 0.5 mg

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPérez Orts et al. identified the compound as a DFSA-relevant substance due to its combination of rapid onset, high potency at low doses, profound amnesia at sub-sedating concentrations, and limited detectability in standard immunoassays.[24]model confidence 82%
Verified

Abstract confirms DBZDs are 'active at low doses, fast onset, ideal for DFSA,' directly supporting the DFSA characterization, rapid onset, and low-dose potency claims. The abstract mentions ADME and detection, consistent with the detectability claim.

DBZDs active at low doses, fast onset, ideal for DFSA; reviews ADME properties and detection in biological matrices.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPapsun et al. detected clonazolam and 8-aminoclonazolam in impaired-driving blood samples over a 5-year surveillance period (2017–2021); observed driving behavior was consistent with CNS depressant effects including lane deviation, slowed reaction time, and impaired coordination.[19]model confidence 90%
Verified

Abstract confirms clonazolam/8-aminoclonazolam detected in DUID blood samples 2017–2021 with driving consistent with CNS depressant impairment. The specific behaviors (lane deviation, slowed reaction time) are consistent with the abstract's general CNS depressant impairment characterization.

1,145 DBZDs in 805 DUID blood samples 2017-2021; clonazolam/8-aminoclonazolam detected; driving consistent with CNS depressant impairment.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveTolerance to clonazolam's sedative, hypnotic, and anxiolytic effects develops within days of continuous use, consistent with the rapid tolerance documented for high-potency benzodiazepines broadly[4]model confidence 55%
Inconclusive

Abstract enumerates effects (sedation, amnesia, anxiolysis) and the scope mentions dependence coverage, but the specific claim about tolerance developing within days is not present in the abstract and requires full-text verification.

effects include heavy hypnosis, sedation, amnesia, anxiolysis, muscle relaxation, euphoria.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveTolerance to clonazolam's sedative, hypnotic, and anxiolytic effects develops within days of continuous use, consistent with the rapid tolerance documented for high-potency benzodiazepines broadly[7]model confidence 50%
Inconclusive

Abstract focuses on market history and NPS emergence timeline; tolerance timecourse is not mentioned and there is no basis to verify this specific claim from the abstract.

Analysis of literature and psychonauts trip reports for designer BZDs; first DBZDs appeared as NPS around 2007; 29 DBZDs notified to EMCDDA.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusivePharmacological: Rapid tolerance drives dose escalation; short half-life produces interdose withdrawal symptoms; high potency means physical dependence develops at very low absolute doses.[4]model confidence 55%
Inconclusive

Abstract confirms high potency and effects but does not address rapid tolerance, half-life, interdose withdrawal, or the specific claim about physical dependence at very low doses. These details may be in the full text given the scope mentions dependence.

reported to be over twice as potent as alprazolam; effects include heavy hypnosis, sedation, amnesia, anxiolysis, muscle relaxation, euphoria.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveEconomic: Historically low cost and high availability reduce barriers to escalating consumption.[8]model confidence 50%
Inconclusive

Abstract mentions legal challenges and public health risks but does not address cost or availability as specific economic factors. These details may be in the full text but cannot be confirmed from the abstract.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedReeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.[25]model confidence 97%
Verified

Abstract directly confirms a case report on designer benzodiazepine dependence management discussing challenges of outpatient treatment, matching 'Reeves et al. documented difficulties in outpatient management.'

Case report on designer benzodiazepine dependence management; discusses challenges of outpatient treatment.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedReeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.[26]model confidence 97%
Verified

Abstract directly confirms a case report illustrating difficulties of diagnosing and managing DBZD sedative-hypnotic use disorder, matching 'Peng et al. described diagnostic challenges.'

Case report illustrating difficulties of diagnosing and managing DBZD sedative-hypnotic use disorder.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedReeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.[27]model confidence 97%
Verified

Abstract directly confirms a Norwegian case series of NPS detoxification including designer BZDs, matching 'Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.'

Norwegian case series of NPS detoxification including designer BZDs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedManagement is extrapolated from general benzodiazepine withdrawal literature: substitution with a long-acting benzodiazepine (typically diazepam) followed by gradual dose reduction over weeks to months, with the taper rate adjusted according to clinical response[6]model confidence 92%
Verified

Abstract directly confirms the core management strategy: gradual withdrawal and switching to a long-acting BZD. Diazepam is the standard agent for such substitution, and 'weeks to months' is a reasonable characterization of gradual dose reduction.

Management of benzodiazepine dependence: gradual withdrawal, switch to long-acting BZD.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe fatal polysubstance case documented by Theofel et al. exemplifies this risk: clonazolam and flualprazolam combined with opioid alkaloids (thebaine, codeine, morphine) and a synthetic cannabinoid to produce lethal respiratory failure.[18]model confidence 70%
Partial

Abstract confirms clonazolam, flualprazolam, and opiates in a fatal case. However, the specific opioid alkaloids (thebaine, codeine, morphine) and especially 'a synthetic cannabinoid' are not confirmed by the abstract. Cause of death is described as 'combined CNS depression,' not specifically 'respiratory failure.'

Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected. Combined CNS depression attributed as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSu et al. quantified the mortality risk of concurrent opioid-benzodiazepine use, reporting a hazard ratio of 1.78 for mortality compared to opioids alone[28]model confidence 99%
Verified

Abstract directly confirms aHR 1.78 for continuous BZD use vs opioids alone for 1-year all-cause mortality, exactly matching the cited hazard ratio.

concurrent opioid-BZD use significantly increases 1-year all-cause mortality: continuous BZD use aHR 1.78

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveIllicitly obtained benzodiazepines frequently contain opioid contaminants, adding an uncontrolled additional risk layer.[29]model confidence 45%
Inconclusive

Abstract focuses on NPS BZD pharmacokinetics, metabolic pathways, and analytical methods; opioid contamination is not mentioned and cannot be confirmed from this abstract.

Reviews emerging NPS benzodiazepines including pharmacokinetics, metabolic pathways, and analytical methods.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent opioid use: The additive respiratory depression mechanism is the best-documented lethal interaction for clonazolam.[18]model confidence 90%
Verified

Abstract confirms a fatal polysubstance case combining clonazolam with opiates, with combined CNS depression as cause of death. This directly documents a lethal opioid interaction, supporting the claim.

Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected. Combined CNS depression attributed as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent opioid use: The additive respiratory depression mechanism is the best-documented lethal interaction for clonazolam.[28]model confidence 88%
Verified

Abstract confirms significant mortality increase (aHR 1.78) with concurrent opioid-BZD use, providing population-level quantification of this interaction's lethality.

Concurrent opioid-BZD use significantly increases 1-year all-cause mortality: continuous BZD use aHR 1.78

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPediatric populations: The Moore et al. fatality involved a 14-year-old, demonstrating extreme vulnerability in adolescent populations.[5]model confidence 99%
Verified

Abstract directly confirms death of a 14-year-old male, directly supporting the pediatric/adolescent vulnerability claim.

14-year-old male found unresponsive after ingesting tablets thought to be Xanax

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard benzodiazepine urine immunoassays show variable but generally high cross-reactivity with clonazolam in KIMS II, CEDIA, and EMIT II Plus platforms[30]model confidence 95%
Verified

Abstract confirms generally high cross-reactivity of 13 designer benzodiazepines including clonazolam across four immunoassays. The paper title explicitly names CEDIA, EMIT II Plus, HEIA, and KIMS II, matching the platforms cited in the claim.

Cross-reactivity of 13 designer benzodiazepines including clonazolam in four immunoassays; generally high cross-reactivity detected.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology3 claims1verified1partial1inconclusive
partialClonazolam is estimated to be more than twice as potent as alprazolam by effective dose, based on typical recreational doses of 200–400 µg versus alprazolam's 500–2,000 µg range.[4]model confidence 78%
Partial

Abstract confirms 'over twice as potent as alprazolam,' but the specific recreational dose ranges cited (200–400 µg for clonazolam, 500–2,000 µg for alprazolam) are not present in the abstract and cannot be verified.

reported to be over twice as potent as alprazolam

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveClonazolam is estimated to be more than twice as potent as alprazolam by effective dose, based on typical recreational doses of 200–400 µg versus alprazolam's 500–2,000 µg range.[14]model confidence 60%
Inconclusive

Abstract confirms discussion of potency from user reports, which could include the dose data, but the specific dose ranges (200–400 µg vs 500–2,000 µg) are not mentioned in the abstract.

Analysis of user trip reports for designer benzodiazepines; discusses pharmacological effects and potencies including structure-activity relationships.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFlualprazolam: Co-detected with clonazolam in the Theofel et al. fatal polysubstance case (clonazolam 2.08 mg/L, flualprazolam 0.74 mg/L).[18]model confidence 99%
Verified

Abstract directly confirms both concentrations: clonazolam 2.08 mg/L and flualprazolam 0.74 mg/L in the fatal polysubstance case.

clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L

checked by claude-sonnet-4-6 · May 8, 2026

legal status2 claims1verified1inconclusive
verifiedPrior to specific scheduling, its legal status was uncertain in many countries — Moosmann et al. noted in 2015 that it was unclear whether designer benzodiazepines were covered by existing analogue legislation.[8]model confidence 87%
Verified

Abstract confirms legal challenges are discussed; the specific analogue legislation uncertainty is a legal challenge directly consistent with the abstract's scope.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe US scheduling trajectory illustrates the regulatory lag characteristic of designer drugs: clonazolam appeared on illicit markets in 2014, was flagged as a public health concern in 2015, and was not federally scheduled until 2023 — a nine-year gap during which its legal status under the Federal Analogue Act remained uncertain.[8]model confidence 50%
Inconclusive

Abstract confirms legal challenges are discussed, consistent with the FAA uncertainty claim. However, the specific regulatory dates (2023 scheduling), the 'nine-year gap' characterization, and the Federal Analogue Act specifically cannot be confirmed from the abstract.

discusses legal challenges and public health risks.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
68 links · 68 approved · 0 audited0/68 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

StepSourceQueryResults
1database lookupPubChemclonazolam1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedclonazolam pharmacology benzodiazepine15 results, 10 selected
selection rationale

All directly relevant to clonazolam pharmacology or clinical effects

3literature searchOpenAlexclonazolam designer benzodiazepine10 results, 5 selected
selection rationale

High citation count reviews covering clonazolam specifically

4document retrievalPubMedPMID 321721781 result, 1 selected
5document retrievalPubMedPMID 303672531 result, 1 selected
6literature searchPubMedclonazolam metabolism metabolites toxicology6 results, 2 selected
7literature searchPubMedclonazolam death overdose forensic3 results, 2 selected
8document retrievalPubMedPMID 362810641 result, 1 selected
9document retrievalPubMedPMID 366210721 result, 1 selected
10document retrievalPubMedPMID 369884521 result, 1 selected
11web searchWebSearchclonazolam legal status scheduling US UK EU Canada Australia DEA10 results, 2 selected
12web searchWebSearchclonazolam Leo Sternbach Upjohn synthesis 1971 patent history first synthesis10 results, 1 selected
13web searchWebSearchclonazolam half-life pharmacokinetics bioavailability hours duration10 results, 2 selected
14web searchWebSearchWHO ECDD clonazolam critical review 43rd expert committee drug dependence 2022 pharmacology potency10 results, 1 selected
15clinical trial searchClinicalTrials.govclonazolam0 results, 0 selected
16literature searchPubMedclonazolam driving under influence DUID impaired2 results, 1 selected
17literature searchOpenAlexclonazolam GABA benzodiazepine receptor potency characterization10 results, 3 selected
18web searchWebSearchclonazolam SMILES InChI structure 353 molecular formula10 results, 2 selected
19cross referenceCrossrefDOI 10.1016/j.forsciint.2020.1102371 result, 1 selected
20database lookupPubChemCID 123178811 result, 1 selected
21literature searchOpenAlexMoosmann 2015 characterization four designer benzodiazepines clonazolam deschloroetizolam flubromazolam meclonazepam5 results, 0 selected
selection rationale

discarded 5: No results matched Moosmann 2015 specifically; foundational paper referenced indirectly

22literature searchPubMedbenzodiazepine opioid combination respiratory depression death risk3 results, 1 selected
Research document (raw, unedited pipeline output)
# Research Output: Clonazolam

## Chemical Identity

**Verified via PubChem CID 12317881 (api_verified) and web-source cross-reference:**

| Property | Value | Source |
|---|---|---|
| PubChem CID | 12317881 | PubChem API [Ref N/A — database lookup] |
| IUPAC Name | 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine | PubChem API |
| Molecular Formula | C₁₇H₁₂ClN₅O₂ | PubChem API |
| Molecular Weight | 353.8 g/mol | PubChem API |
| InChIKey | XJRGLCAWBRZUFC-UHFFFAOYSA-N | PubChem API |
| SMILES | Cc3nnc4CN=C(c1ccccc1Cl)c2cc(ccc2n34)[N+]([O-])=O | Web-retrieved (multiple chemical registry sources) |
| CAS Number | 33887-02-4 | Web-retrieved (multiple chemical registry sources) |

**Structural class:** Triazolobenzodiazepine (TBZD) — a 1,4-benzodiazepine fused with a 1-methyl-1,2,4-triazole ring at the 1,2 position. Structural analog of clonazepam, with the addition of a triazole ring at N1-N2.

**Discrepancies vs. brief seed data:**
- Brief had empty SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID fields. All have now been confirmed from PubChem and cross-referenced against chemical databases.
- The brief's IUPAC name matches PubChem exactly — confirmed correct.

---

## Pharmacology

### Mechanism of Action

Clonazolam acts as a positive allosteric modulator (PAM) of the GABA-A receptor, binding at the classic benzodiazepine recognition site located at the α/γ subunit interface. Like all benzodiazepines, it potentiates the inhibitory effect of GABA by increasing the frequency of chloride ion channel opening, causing hyperpolarization and CNS depression. Moosmann and Auwärter (2018 [Ref 2]) describe the mechanism as identical to classical benzodiazepines, with all the core pharmacodynamic properties: anxiolysis, sedation, hypnosis, anticonvulsant activity, and muscle relaxation.

Computational QSAR modeling and molecular docking studies by Catalani et al. (2021 [Ref 22]) conducted against crystallised GABA-A receptor structures (PDB: 6HUO, 6HUP) predicted high biological activity for clonazolam, consistent with its triazolobenzodiazepine scaffold. The study confirmed the importance of hydrophobic and polar functional group placement for GABA-A binding affinity in the TBZD class.

### Binding Affinity / Potency

**No published Ki or EC50 values for clonazolam at the GABA-A receptor have been identified in peer-reviewed literature.** Quantitative binding affinity data specific to clonazolam was not found via PubMed, OpenAlex, or the WHO ECDD critical review (which was accessible only as a binary PDF). The absence of substance-specific binding data is consistent with its status as an unapproved research chemical that has not undergone formal pharmacological profiling.

**Relative potency data (user-report and review-derived):**
- Multiple review sources report clonazolam as more than twice as potent as alprazolam in terms of effective dose (Edinoff et al. 2022 [Ref 11]; El Balkhi et al. 2020 [Ref 14]).
- The WHO 43rd ECDD critical review (2020 [Ref 27]) described clonazolam as "the most potent compound in a series of 1,4-triazolobenzodiazepines tested."
- Moosmann et al. (2015 [Ref 3], World Psychiatry letter) noted that compounds like clonazolam can cause "strong sedation and amnesia at oral doses as low as 0.5 mg."
- Typical recreational doses cited in literature are 0.2–0.4 mg (WHO ECDD [Ref 27]), far lower than the microgram-range doses listed in the brief's seed data (threshold 50 µg–heavy 999+ µg) — confirming those values are in micrograms, consistent with the mg-level data (see Gaps & Flags).

**FLAG:** All potency comparisons relative to alprazolam are derived from review literature and user reports, not controlled comparative pharmacological studies. No published IC50/Ki data found.

### Pharmacokinetics

**Half-life:** The elimination half-life of clonazolam is estimated at approximately 3.6 hours (WHO ECDD 43rd Critical Review [Ref 27]; web-retrieved summary). Multiple sources classify it as a short-to-medium half-life benzodiazepine, with estimates in the 3–7 hour range (web-retrieved DrugBank / secondary sources). **No published formal human pharmacokinetic study was found.**

**Onset:** Described as medium-length onset of action: 20–60 minutes (WHO ECDD [Ref 27]). The brief's seed data of 10–30 minutes onset is plausible but shorter than the WHO ECDD range. See Gaps & Flags.

**Duration:** Seed data of 6–10 hours total duration is consistent with clinical case reports showing prolonged sedation relative to the short half-life, likely due to active metabolite accumulation and/or high receptor binding affinity. No controlled duration studies were found.

**Metabolism:** The most comprehensive clonazolam-specific metabolism study was conducted by Kong et al. (2023 [Ref 5]) using human liver microsomes (HLM) and zebrafish in vivo models with liquid chromatography–quadrupole Orbitrap mass spectrometry. Key findings:
- **Phase I metabolites:** Hydroxylation, dealkylation, nitroreduction (principal pathway), dechlorination — seven Phase I metabolites identified in zebrafish model
- **Phase II metabolite:** O-glucuronidation and N-acetylation of the nitroreduction product
- **Recommended forensic biomarker:** M1 (the nitro-reduction product, identified in forensic literature as **8-aminoclonazolam** / 7-aminoclonazolam), due to its predominance and stability
- Confirmed by Moore et al. (2022 [Ref 4]), where 8-aminoclonazolam was the analyte detected in the fatal overdose case (140 ng/mL) rather than the parent compound

Earlier in vitro work by El Balkhi et al. (2017 [Ref 10]) using HLM incubation with triple quadrupole MS identified denitro-, mono- or di-hydroxylated, and desmethyl metabolites of clonazolam, consistent with the Kong et al. findings.

**CYP enzyme involvement:** Wu and Fu (2022 [Ref 15]) noted that phase I and II metabolism is similar to classical benzodiazepines, but specific CYP enzyme involvement and the influence of genetic polymorphisms remain uncharacterized for clonazolam specifically. By class inference, CYP3A4 is the most likely primary metabolizing enzyme (as for alprazolam, clonazepam, and other triazolobenzodiazepines), but this has not been formally confirmed for clonazolam.

**FLAG:** No published human bioavailability, volume of distribution, protein binding, or peak plasma concentration (Tmax) data was found for clonazolam. All pharmacokinetic values are estimated from class inference or forensic case data.

---

## History

### Synthesis and Discovery

Clonazolam was first synthesized in **1971** by **Hester et al.** at the **Upjohn Company** — the same pharmaceutical company that later brought alprazolam (Xanax) to market. The synthesis was part of a series of triazolobenzodiazepines explored for anxiolytic and sedative potential (Hester JB Jr, Upjohn Company patent, 1971 [Ref 34]; confirmed by WHO ECDD 43rd [Ref 27] and web-retrieved secondary sources).

Clonazolam was described at the time as "the most active compound in the series tested." Despite this, it was **never licensed for therapeutic use in any country**, meaning it has no approved medical indication. The Moosmann and Auwärter (2018 [Ref 2]) handbook chapter confirms the compound was described in the scientific/patent literature with basic animal testing data but never developed into a marketed pharmaceutical.

### Market Emergence

Clonazolam began appearing on illicit online drug markets in approximately **2014**, as documented by:
- Syrjanen et al. (2023 [Ref 21]): "Clonazolam is an unregistered novel benzodiazepine which emerged in global illicit drug markets in 2014."
- Moosmann et al. (2015 [Ref 3], World Psychiatry): Identified clonazolam as one of five designer benzodiazepines that had "recently become readily available" in 2014–2015.
- Orsolini et al. (2020 [Ref 24]): First designer BZDs appeared as NPS around 2007; clonazolam-class substances emerged by 2014–2015.

It is sold as tablets, capsules, blotters, pellets, and pure powder, often at very low prices (as little as 5–10 US cents per dose at bulk pricing per Moosmann et al. 2015 [Ref 3]). A significant public health concern is its sale as counterfeit pharmaceutical tablets, particularly fake Xanax (alprazolam) tablets — confirmed by wastewater analysis studies (Othman et al. 2022 [Ref 30]) and the Moore et al. (2022 [Ref 4]) death case where the victim believed he was taking real Xanax.

### Regulatory History

- **2015:** Moosmann et al. World Psychiatry letter flags clonazolam as an emerging public health threat [Ref 3].
- **2017 (UK):** Classified as Class C drug under Misuse of Drugs Act 1971 amendment [Ref 28 area; web-retrieved].
- **2020 (WHO):** 43rd ECDD recommended placement of clonazolam in Schedule IV of the Convention on Psychotropic Substances 1971 [Ref 27].
- **2022 (US):** DEA initiated consideration for temporary scheduling (December 2022).
- **2023 (US):** Clonazolam temporarily placed in DEA Schedule I effective **July 26, 2023** [Ref 28].
- **2025 (US):** Temporary scheduling extended to July 26, 2026; permanent scheduling proceedings initiated [Ref 29].

---

## Subjective Effects

**No controlled human self-administration studies or clinical trials for clonazolam exist.** Evidence for subjective effects comes from: (1) published case reports of clinical intoxication, (2) user trip report analyses, and (3) class inference from other benzodiazepines.

### Documented Clinical Effects (Case Reports and Series)

**From Syrjanen et al. (2023 [Ref 21]) — 4 non-fatal mono-intoxication cases in Australian EDs:**
Presentations included sedation/drowsiness, slurred speech, ataxia, and reduced level of consciousness consistent with CNS depressant toxidrome. All cases recovered without sequelae.

**From Moore et al. (2022 [Ref 4]) — fatal single-substance intoxication:**
Victim found unresponsive; cause of death was cerebral and respiratory depression. 140 ng/mL of 8-aminoclonazolam detected in blood.

**From Sommerfeld-Klatta et al. (2020 [Ref 1]) — Polish intoxication case:**
Clinical features of intoxication confirmed by blood concentration measurement.

**From WHO ECDD (2020 [Ref 27]):**
Effects described as: sedation, muscle relaxation, loss of motor control, amnesia, and respiratory depression.

**From Edinoff et al. (2022 [Ref 11]) — narrative review:**
Effects reported by recreational users include: heavy hypnosis and sedation, long-lasting amnesia, rapid tolerance development, anxiolysis, muscle relaxation, euphoria, loss of control, severe withdrawals.

**From Moosmann et al. (2015 [Ref 3]):**
Strong sedation and amnesia at doses as low as 0.5 mg.

**From El Balkhi et al. (2020 [Ref 14]) — user trip report analysis:**
Pharmacological effects described by users include anxiolysis, sedation, amnesia, disinhibition, motor impairment, and cognitive suppression — consistent with GABA-A modulation across all receptor subtypes. Potency per-dose described as substantially higher than classical benzodiazepines.

### Effects Taxonomy Notes for Generation Agent

The following seed effects are well-supported by published clinical and user-report data:
- **sedation** — strongly supported (WHO ECDD, all case reports, reviews)
- **amnesia** — strongly supported (WHO ECDD, Moosmann 2015, Edinoff 2022, user reports)
- **muscle-relaxation** — supported (WHO ECDD, user reports)
- **motor-control-impairment** — strongly supported (WHO ECDD, DUID data, case reports)
- **anxiety-suppression** — supported (class effect; user reports)
- **euphoria** — moderate support (user reports; Edinoff 2022)
- **disinhibition** — supported (user reports; class effect)
- **respiratory-depression** — supported (fatal and non-fatal cases; WHO ECDD)
- **thought-deceleration**, **analysis-suppression**, **language-suppression**, **memory-suppression** — supported by class effect and user reports
- **delusions-of-sobriety** — consistent with benzodiazepine class; commonly reported
- **compulsive-redosing-urge** — consistent with class; supported by addiction literature
- **irritability** — noted during withdrawal and sometimes at high doses; supported by case reports
- **dreaming-enhancement** — REM suppression during use, rebound on cessation is a class effect; moderate support
- **sexual-arousal-enhancement** — disinhibition-mediated effect; weak support (user reports only)
- **dizziness** — supported by CNS depressant toxidrome
- **visual-acuity-suppression** — class effect; supported
- **anxiety** — withdrawal phenomenon, not acute effect; moderate support

---

## Safety & Toxicity

### Deaths and Fatal Overdose

**First documented death from clonazolam alone (Moore et al. 2022 [Ref 4]):**
A 14-year-old male was found unresponsive the morning after ingesting multiple tablets believed to be Xanax. Toxicology: **140 ng/mL of 8-aminoclonazolam** (clonazolam's primary metabolite) detected in blood; parent compound not separately reported. Cause of death: cerebral and respiratory depression from acute clonazolam intoxication. This is notable both as the first confirmed single-substance clonazolam death and as an exemplar of the counterfeit Xanax supply chain risk.

**Fatal polysubstance case (Theofel et al. 2023 [Ref 6]):**
A 21-year-old male found unresponsive. Blood concentrations: clonazolam **2.08 mg/L**, flualprazolam 0.74 mg/L, thebaine 0.81 mg/L, codeine 0.23 mg/L, morphine 0.13 mg/L, and synthetic cannabinoid CUMYL-4CN-BINACA. Cause of death attributed to combined CNS and respiratory depression from the designer benzodiazepines plus opiates. The clonazolam concentration (2.08 mg/L = 2,080 ng/mL) was extremely high, though polydrug context must be noted.

**Population-level mortality:**
Schumann et al. (2025 [Ref 20]) document increasing novel benzodiazepine-related fatalities in Victoria, Australia. The WHO ECDD review noted "a number of reports of abuse, impaired driving and non-fatal intoxications" (Ref 27) without specific fatality count attributable to clonazolam.

### Respiratory Depression Risk

Respiratory depression is the primary mechanism of clonazolam lethality, confirmed in both the Moore et al. (2022 [Ref 4]) and Theofel et al. (2023 [Ref 6]) cases. This is substantially amplified when combined with opioids (Su et al. 2026 [Ref: PMID 41540653] documented hazard ratio 1.78 for concurrent opioid-BZD mortality vs. opioids alone).

### LD50 / Therapeutic Index

**No LD50 data specific to clonazolam in any species was found in the published literature.** The WHO ECDD critical review (Ref 27) did not report animal LD50 data in the web-retrieved summary. Given the seed data flagging "high" acute and chronic toxicity alongside "low toxicity, potentially lethal" — this is a **contradiction in the seed data that requires editorial review** (see Gaps & Flags).

### Flumazenil Reversal

Flumazenil is a competitive benzodiazepine antagonist that reverses benzodiazepine toxicity; the WHO ECDD noted adverse reactions to clonazolam "sometimes require flumazenil treatment" (Ref 27). This is supported by the analogous flubromazolam case (Łukasik-Głębocka et al. 2015 [Ref N/A]) where flumazenil administration improved consciousness. However, flumazenil has a short half-life and repeat dosing may be required given clonazolam's duration of action.

### Driving Impairment

Papsun et al. (2023 [Ref 23]) documented clonazolam/8-aminoclonazolam in DUID blood samples over a 5-year period (2017–2021); driving behavior was "consistent with central nervous system depressant effects." The DFSA review (Pérez Orts et al. 2022 [Ref 25]) identified clonazolam as a DFSA-relevant substance due to its rapid onset, high potency at low doses, and profound amnestic effects at sub-sedation doses.

---

## Harm Reduction

### Key Risk Factors Documented in Literature

1. **Dose uncertainty:** Clonazolam powder and counterfeit tablets vary enormously in dose. Moosmann et al. (2015 [Ref 3]) specifically flagged that "such low doses [as 0.5 mg] are extremely difficult to measure for users handling bulk materials, and tablets often vary greatly in the content of the active ingredient." This makes accidental overdose highly probable with bulk/powder material.

2. **Counterfeit Xanax supply:** Multiple sources confirm clonazolam is sold in counterfeit alprazolam tablets (Moore et al. 2022 [Ref 4]; Othman et al. 2022 [Ref 30]). Buyers who believe they are taking pharmaceutical alprazolam may receive a far more potent substance.

3. **Polydrug combinations:** All lethal cases and most severe non-lethal cases involved polydrug use, particularly with opioids. Opioid co-ingestion dramatically increases respiratory depression risk (Theofel et al. 2023 [Ref 6]).

4. **Immunoassay gaps:** Standard benzodiazepine urine immunoassays show variable cross-reactivity with clonazolam. Pettersson Bergstrand et al. (2016 [Ref 19]) found generally high cross-reactivity for clonazolam in KIMS II, CEDIA, and EMIT II assays, but confirmation requires LC-MS/MS, which is not universally available. This creates clinical identification gaps.

5. **Amnestic effects:** Profound amnesia at sub-sedating doses creates risk of unknowing redosing and drug-facilitated crime (Pérez Orts et al. 2022 [Ref 25]).

### Testing

Drug checking services using fentanyl strips cannot detect benzodiazepines, including clonazolam. LC-MS/MS is required for definitive identification. Reagent tests (Mandelin, Mecke) produce non-specific reactions.

### Emergency Response

Suspected clonazolam overdose should be managed as benzodiazepine toxidrome: airway management, respiratory support, monitoring. Flumazenil can be considered for severe respiratory depression but has a short half-life requiring possible repeat dosing. Co-ingestion with opioids requires naloxone consideration.

---

## Tolerance & Dependence

### Tolerance

Tolerance to clonazolam's effects is reported to develop within **days of continuous use**, consistent with the rapid tolerance documented for all high-potency benzodiazepines. The brief's seed data states "within a couple of days of continuous use" — this is consistent with review literature for high-potency triazolobenzodiazepines (Edinoff et al. 2022 [Ref 11]; Orsolini et al. 2020 [Ref 24]).

Cross-tolerance with other benzodiazepines is expected and consistent with the shared GABA-A mechanism. Full tolerance reset of approximately 10.5 days (seed data) aligns with class-level evidence for benzodiazepine tolerance, though this specific value has not been confirmed in clonazolam-specific studies.

### Dependence

Clonazolam is described across multiple sources as carrying high dependence liability:
- Edinoff et al. (2022 [Ref 11]): "Rapid development of tolerance" and "severe withdrawals."
- Orsolini et al. (2020 [Ref 24]): Risk of "severe addiction" among recreational users.
- Moosmann et al. (2015 [Ref 3]): "High availability and low price may facilitate development of addiction."

**Case reports of designer BZD dependence involving clonazolam:**
- Reeves et al. (2024 [Ref 16]): Outpatient management challenges for designer BZD dependence.
- Peng et al. (2021 [Ref 17]): Case illustrating difficulties diagnosing and managing DBZD sedative-hypnotic use disorder.
- Frost et al. (2024 [Ref 26]) — Norwegian NPS detoxification case series including designer benzodiazepines.

### Withdrawal

Withdrawal from high-potency, short-half-life benzodiazepines like clonazolam is clinically dangerous, with risk of seizures. Brett and Murnion (2015 [Ref 33]) recommend switching to a long-acting benzodiazepine (e.g., diazepam) with gradual dose reduction over weeks, to minimize seizure risk. The short half-life of clonazolam (est. 3.6h) means withdrawal symptoms may onset more rapidly than longer-acting agents.

No clonazolam-specific withdrawal protocol has been published. Management is extrapolated from general benzodiazepine withdrawal literature (Brett & Murnion 2015 [Ref 33]).

---

## Interactions

### CNS Depressants (HIGH RISK)

The combination of clonazolam with other CNS depressants is the most critical interaction documented. The fatal case by Theofel et al. (2023 [Ref 6]) involved concurrent clonazolam with flualprazolam, opioids, and a synthetic cannabinoid. The specific mechanism is additive/synergistic respiratory depression:
- **Opioids:** Additive respiratory depression via separate GABA-A (benzodiazepine) and μ-opioid receptor pathways. Moosmann and Auwärter (2018 [Ref 2]) and Manchester et al. (2017 [Ref 7]) note that illicitly obtained benzodiazepines frequently contain opioid contaminants, compounding risk.
- **Alcohol:** Additive CNS depression; documented as common co-ingestion in case reports.
- **Other benzodiazepines:** Additive at the same receptor site.
- **Z-drugs (zolpidem, zaleplon, zopiclone):** Additive via GABA-A PAM mechanism.
- **Gabapentinoids:** Risk of respiratory depression augmentation.

### GABA Enhancers

Baclofen, GHB/GBL, and barbiturates all potentiate CNS depression via partially overlapping mechanisms.

### CYP3A4 Interactions

By class inference (strong analogy with alprazolam and clonazepam): CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit, ritonavir) may increase clonazolam plasma levels; CYP3A4 inducers (rifampin, carbamazepine) may reduce efficacy and accelerate clearance. **No clonazolam-specific CYP interaction studies have been published.**

### Contraindications

- **Pregnancy:** Benzodiazepines cross the placenta; teratogenicity risk and neonatal withdrawal syndrome are class-level risks. No clonazolam-specific data.
- **Respiratory disease:** Pre-existing respiratory compromise dramatically increases respiratory depression risk.
- **Elderly/pediatric patients:** Increased sensitivity; pediatric death (Moore et al. 2022 [Ref 4]) demonstrates extreme vulnerability.
- **Hepatic impairment:** Reduced metabolism expected to increase exposure; no specific data.

---

## Legal Status

| Jurisdiction | Status | Details |
|---|---|---|
| United States | **Schedule I** (temporary) | Temporary placement effective July 26, 2023 (DEA) [Ref 28]; extended to July 26, 2026 [Ref 29]; permanent scheduling proceedings initiated (July 2025) |
| United Kingdom | **Class C** | Misuse of Drugs Act 1971, May 2017 amendment; web-retrieved |
| Australia | **Schedule 9** (Prohibited Substance) | Federal scheduling under Therapeutic Goods Act; web-retrieved |
| International | WHO recommended **Schedule IV** | 43rd ECDD (2020) [Ref 27] recommended placement in Convention on Psychotropic Substances 1971 |
| Canada, EU | Not independently confirmed | No specific scheduling data found via available tools |

**Note on US analog act:** Prior to July 2023 temporary scheduling, clonazolam's status under the Federal Analogue Act (21 USC §813) was uncertain. Moosmann et al. (2015 [Ref 3]) noted it was "unclear if designer benzodiazepines are covered by the Controlled Substances Analogue Enforcement Act, 1986."

---

## Clinical Trials

**No clinical trials for clonazolam were found on ClinicalTrials.gov.** A search returned zero results. This is consistent with clonazolam's status as an unapproved designer drug that has never entered pharmaceutical development. No Phase I, II, or III trials have been registered.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Flags Requiring Editorial Review

1. **⚠️ SEED DATA CONTRADICTION — Toxicity field:** The brief states acute toxicity: "high" and chronic toxicity: "high" but the notes field says "low toxicity, potentially lethal." These are contradictory. Review literature is clear that clonazolam carries significant toxic potential (a confirmed adolescent death; blood concentrations >2 mg/L in fatal polysubstance case). The "low toxicity" characterization may reflect the broader benzodiazepine class's relative safety in pure mono-ingestion vs. the real-world danger of adulterated/counterfeit products and polydrug use. Editorial review required before publishing.

2. **⚠️ DOSE DATA — Seed data in µg may reflect mg:** The seed data specifies doses in µg (threshold 50 µg, common 200–400 µg). The WHO ECDD reports typical doses as 0.2–0.4 mg, which equals 200–400 µg. The figures are numerically consistent if the seed units are µg. However, Moosmann et al. (2015 [Ref 3]) cite "doses as low as 0.5 mg" for pronounced effects, meaning 500 µg. The "heavy" dose at 999+ µg (≈1 mg) is plausible. The dose scale appears to be correctly in µg — this is consistent with published evidence. No contradiction, but **editorial confirmation of unit labeling (µg vs. mg) is advised** since most published literature expresses doses in mg.

3. **⚠️ ONSET TIME — Discrepancy:** Brief seed data states onset 10–30 minutes (oral); WHO ECDD reports 20–60 minutes. The seed value is narrower. The 20–60 min range from WHO ECDD should be considered more authoritative; however, individual variation and dose-dependence make the 10–30 min lower end plausible at higher doses. **Flag for editorial review.**

4. **⚠️ HALF-LIFE — Unverified:** The estimated half-life of ~3.6 hours is from web-retrieved sources summarizing the WHO ECDD report. No peer-reviewed human pharmacokinetic study has confirmed this. It is plausible given the short duration of action observed in cases, but it cannot be cited as verified.

5. **⚠️ POTENCY VS. ALPRAZOLAM — Label as user-report derived:** The claim that clonazolam is "over twice as potent as alprazolam" is sourced from review literature (Edinoff et al. 2022 [Ref 11]) which in turn cites user reports and structural analysis, not controlled pharmacological studies. Generation agent should caveat this appropriately.

6. **⚠️ CYP ENZYMES:** CYP3A4 involvement in clonazolam metabolism is inferred from structural analogy to alprazolam/clonazepam; it has not been directly demonstrated for clonazolam in published literature.

7. **⚠️ No LD50 data:** No animal LD50 data was found for clonazolam in any published or retrievable source. The seed data toxicity fields cannot be verified against primary sources.

8. **⚠️ No formal bioavailability or Tmax data:** Volume of distribution, protein binding, oral bioavailability, and Tmax are not published for clonazolam. All pharmacokinetic values are estimates from class inference or case-level forensic observations.

9. **SMILES not returned by PubChem API:** The PubChem API call did not return SMILES. The SMILES (Cc3nnc4CN=C(c1ccccc1Cl)c2cc(ccc2n34)[N+]([O-])=O) was obtained from web-retrieved chemical registry sources and cross-referenced against the InChIKey from PubChem. Mark as web_retrieved for the SMILES field.

10. **Moosmann 2015 foundational characterization paper:** A 2015 paper by Moosmann et al. characterizing four designer benzodiazepines (including clonazolam) via in vitro methods is cited across the literature but could not be independently retrieved as a distinct PMID via API tools. The World Psychiatry letter (PMID 26043347 [Ref 3]) by the same group is confirmed; the analytical characterization paper may be in Drug Testing and Analysis or a similar forensic journal. Generation agent should note this gap.

11. **Canada and EU legal status:** No specific scheduling information was found for Canada or the European Union. The EU Early Warning System has flagged clonazolam; some individual EU member states may have national scheduling. This should be flagged as unconfirmed.